dc.contributor.author | Osuji, N | |
dc.contributor.author | Matutes, E | |
dc.contributor.author | Tjonnfjord, G | |
dc.contributor.author | Grech, H | |
dc.contributor.author | Del Giudice, I | |
dc.contributor.author | Wotherspoon, A | |
dc.contributor.author | Swansbury, JG | |
dc.contributor.author | Catovsky, D | |
dc.date.accessioned | 2018-09-03T13:11:22Z | |
dc.date.issued | 2006-08-01 | |
dc.identifier | 3 | |
dc.identifier.citation | CANCER, 2006, 107 pp. 570 - 578 | |
dc.identifier.issn | 0008-543X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2520 | |
dc.identifier.eissn | 1097-0142 | |
dc.identifier.doi | 10.1002/cncr.22032 | |
dc.description.abstract | BACKGROUND. To the authors’ knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies. METHODS. The authors report on the use of immunosuppressants (cyclosporin A [CSA] and low-dose oral methotrexate [MTX] given continuously) and cytotoxic agents in the treatment of 29 patients with T-cell LGL leukemia age over the past 20 years. RESULTS. The overall response rate (ORR) to MTX (n = 8 patients) was 85.7% (complete hematologic response [CHR] rate, 14.3%; partial response [PR] rate, 71.4%) with dose-dependent responses observed and safe usage of doses > 10 mg/m(2) per week in 2 patients. The ORR to CSA (n = 23 patients). was 78.2% (CHR rate, 30.4%; PR rate, 47.8%). The median time to response for both agents was I month. Toxicity; although it was minor in most patients and was more common in the CSA group, included second malignancies in 5 patients. An ORR of 67% (all CHR) was attained with pentostatin (n = 4 patients); recurrences developed after a median of 4.6 years. Successful retreatment with pentostatin was possible but with increasing drug resistance. Cyclophosphamide induced CHR that lasted > 7 years with bone marrow clearance in 1 of 4 patients. Alemtuzumab induced a PR in 1 patient who had refractory disease. CONCLUSIONS. Both MTX and CSA were efficacious in the treatment of T-cell LGL leukemia but generally required long-term maintenance therapy. The authors highlight the risks of second malignancies and persistence of bone marrow disease. Although MTX and CSA were effective as first-line therapy, alemtuzumab and pentostatin merit further investigation, particularly for refractory disease. | |
dc.format.extent | 570 - 578 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.title | T-cell large granular lymphocyte leukemia - A report on the treatment of 29 patients and a review of the literature | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1002/cncr.22032 | |
rioxxterms.licenseref.startdate | 2006-08-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | CANCER | |
pubs.notes | researcherid-numbers: Del Giudice, Ilaria/K-6027-2016 orcid-numbers: Del Giudice, Ilaria/0000-0001-6864-9533 unique-id: ISI:000239157800017 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.volume | 107 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Molecular Haematology (including Cytogenetics Group and Cell Markers) | en_US |
dc.contributor.icrauthor | Matutes, Estella | en |